| FORM PTO 1449 (modified)                          | Atty. Docket No.<br>X-16501                       | Serial No<br>10/574649 |
|---|---|------------------------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | First Applicant Guoqing Cao                       |                        |
|   | Application Date                                  | Group Art Unit         |
|   | October 7, 2004<br>US Nat'l Entry (if applicable) | 1624                   |
|   |   |                        |

| U.S. PATEN6T DOCUMENTS |               |   |                                |  |  |
|------------------------|---------------|---|--------------------------------|--|--|
| Examiner<br>Initials*  | Cite<br>No. 1 | Document Number  Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Pages |
|                        | 110.          | rumou-kind code   |                                |  | or Relevant Figures<br>Appear                  |
| /B.C./                 | AU            | US 2005/234212  | 10-20-2005                     | Depuydt et al.                                     |  |
| /B.C./                 | AV            | US 2006/100239  | 05-11-2006                     | Nagasaki et al                                     | *  |

| Examiner              | Cite | Foreign Patent Document  |   | Name of Patentee or   | n cl I' m   | т6             |
|-----------------------|------|--|---|---|---|----------------|
| Initials*             | No.1 | Country Code <sup>3</sup> -Number <sup>4-</sup><br>Kind Code5 (if known)                   | Publication Date<br>MM-DD-YYYY              | Applicant of Cited Document   | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |                |
| /B.C./                | BA   | WO 01/40190 A1   | 06-07-2001                                  | Pfizer Products Inc.  |   |                |
| /B.C./                | BB   | WO 05/033082 A2, A3  | 04-14-2005                                  | Pfizer Products, Inc.   |   |                |
| /B.C./                | BC   | EP 1,125,929   | 11-13-2000                                  | Pfizer Products, Inc.   |   |                |
| /B.C./                | BD   | JP 19972214746A  | 08-26-1997                                  | OTSUKA<br>PHARMACEUTICAL<br>CO. LTD.  |   |                |
| Examiner<br>Initials* | Cite | Include name of the author   | (in CAPITAL LETTI<br>erial, symposium, cata | ATURE DOCUME  BRS), title of the article (when a log, etc.), date, page(s), volum | appropriate), title of the item   | T <sup>6</sup> |
|                       | CA   | city and/or country where published.  Bisgaier et al. J of Lipid Res. 1993, 34, 1625-1634. |   |   |   |                |
| /B.C./                | LA   | Bisgarer et al. 3 of Explu   | 1775, 54, 102                               | J 1054.   |   |                |

| Examiner  | /Dranda Calaman/  | Date Considered 04/44/0000 |  |
|-----------|-------------------|----------------------------|--|
| Signature | /brenda Golenian/ | 04/11/2009                 |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to their Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.